Skip to main content

We are delighted to announce AGC Pharma Chemicals’ participation in BOS Basel, scheduled for June 19th to 20th in Basel, Switzerland.

BOS Basel’s scope is primarily development stage CMC outsourcing for Small Molecules. This means it offers a unique opportunity to connect with specialized experts and decision-makers in the field.

As a CDMO, at AGC Pharma Chemicals, we excel in providing comprehensive solutions for Small Molecules development and manufacturing. Our presence at BOS Basel will focus on our extensive experience in process development, scalable API life cycle management, and our state-of-the-art technology portfolio. We are dedicated to offering excellent, agile, and innovative processes, from raw material sourcing to final product delivery, ensuring your projects achieve success in a cost-effective manner.

Visit our booth 12 at BOS Basel to discover how we can enhance your biopharmaceutical projects with our approaches and expertise!

Latest News

AGC PharmaEvents & ConventionsAGC Pharma Chemicals at CPHI Milan 2024: Let’s talk small molecule innovation
30th September 2024

AGC Pharma Chemicals at CPHI Milan 2024: Let’s talk small molecule innovation

AGC Pharma Chemicals is thrilled to announce its participation at CPHI Milan 2024, taking place from October 8-10. CPHI Milan unites industry leaders, pharma professionals and business of all sizes under…
AGC PharmaEvents & ConventionsAGC Pharma Chemicals at NLSDays 2024
10th September 2024

AGC Pharma Chemicals at NLSDays 2024

We are delighted to announce AGC Pharma Chemicals’ participation in NLSDays 2024, scheduled for September 18th to 19th in Malmö, Sweden. The largest Nordic partnering conference dedicated to the life…
AGC PharmaResources & DevelopmentCarbon Footprint and CDMOs: How is AGC Pharma Chemicals addressing it?
24th July 2024

Carbon Footprint and CDMOs: How is AGC Pharma Chemicals addressing it?

The production of medicines, while vital for human health, leaves a substantial environmental footprint. According to the Sustainable Markets Initiative (SMI), the Biopharmacy industry is responsible for 4–5% of all…